Colorectal Cancer
New Study Results Boost Evidence for Natera's MRD Assays to Guide Adjuvant Therapy Decisions
Premium
The data, from a large prospective cohort, support the value of chemotherapy for ctDNA-positive patients, regardless of clinical stage.
Geneoscopy Submits PMA Application to FDA for Stool-Based Colorectal Cancer Screening Test
The application is supported by data from the company's prospective trial, demonstrating 94 percent sensitivity for CRC in an average-risk cohort.
The company believes the new results, from an initial prospective multisite trial, reflect what it can achieve in the larger cohort that it is now planning to recruit.
Guardant Health, Royal Marsden Partner on Prospective Liquid Biopsy Trial in Early Colorectal Cancer
The study is evaluating the Guardant Reveal assay to guide chemotherapy treatment decisions following surgery for stage II to III colorectal cancer.
The firm is developing a shoebox-size gas chromatography instrument that could be used for routine screenings and critical illness detection and monitoring.